Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O43414
UPID:
ERI3_HUMAN
Alternative names:
Prion interactor 1; Prion protein-interacting protein
Alternative UPACC:
O43414; B1AK98; Q5T2T7; Q5T2T9; Q5TG35; Q9BQA0; Q9UEB4
Background:
ERI1 exoribonuclease 3, also known as Prion interactor 1 and Prion protein-interacting protein, plays a crucial role in RNA metabolism and the RNA interference pathway. Its ability to interact with prion proteins suggests a unique function in cellular biology, potentially linking it to neurodegenerative processes.
Therapeutic significance:
Understanding the role of ERI1 exoribonuclease 3 could open doors to potential therapeutic strategies. Its involvement in RNA processing and interaction with prion proteins positions it as a key target for research in neurodegenerative disease treatment.